Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly

Niimi, Yoshiki; Janelidze, Shorena; Sato, Kenichiro; Tomita, Naoki; Tsukamoto, Tadashi; Kato, Takashi; Yoshiyama, Kenji; Kowa, Hisatomo; Iwata, Atsushi; Ihara, Ryoko; Suzuki, Kazushi; Kasuga, Kensaku; Ikeuchi, Takeshi; Ishii, Kenji; Ito, Kengo; Nakamura, Akinori; Senda, Michio; Day, Theresa A.; Burnham, Samantha C.; Iaccarino, Leonardo; Pontecorvo, Michael J.; Hansson, Oskar; Iwatsubo, Takeshi

doi:10.1186/s13195-024-01469-w

Alzheimer's Research & Therapy

Table 5 AUC, sensitivity, specificity, PPV, NPV, AIC by individual modeling in the BioFINDER cohort

From: Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly

		AUC (95% CI)	sensitivity	specificity	PPV	NPV	AIC
a)	Total (N = 175)^a
	Aβ42/40	0.810 (0.746–0.874)	0.826	0.670	0.620	0.855	184.47
	Aβ42/40 + Age + Sex + APOE	0.869 (0.816–0.921)	0.797	0.792	0.714	0.857	165.09
	p-tau217	0.837 (0.773–0.902)	0.710	0.868	0.778	0.821	164.45
	p-tau217 + Age + Sex + APOE	0.898 (0.849–0.947)	0.826	0.840	0.770	0.881	144.57
	p-tau217/Aβ42	0.859 (0.804–0.915)	0.710	0.849	0.754	0.818	162.24
	p-tau217/Aβ42 + Age + Sex + APOE	0.903 (0.857–0.948)	0.841	0.821	0.753	0.888	142.97
	p-tau217 + Aβ42/40	0.906 (0.861–0.950)	0.768	0.896	0.828	0.856	138.40
	p-tau217 + Aβ42/40 + Age + Sex + APOE	0.925 (0.886–0.965)	0.870	0.887	0.833	0.913	129.28
b)	CU group (N = 112)
	Aβ42/40	0.828 (0.744–0.912)	0.871	0.667	0.500	0.931	103.10
	Aβ42/40 + Age + Sex + APOE	0.891 (0.830–0.952)	0.871	0.778	0.600	0.940	91.23
	p-tau217	0.830 (0.740–0.919)	0.677	0.877	0.677	0.877	96.34
	p-tau217 + Age + Sex + APOE	0.900 (0.833–0.967)	0.839	0.827	0.650	0.931	86.23
	p-tau217/Aβ42	0.845 (0.765–0.926)	0.774	0.778	0.571	0.900	96.73
	p-tau217/Aβ42 + Age + Sex + APOE	0.898 (0.834–0.963)	0.839	0.827	0.650	0.931	86.59
	p-tau217 + Aβ42/40	0.916 (0.864–0.968)	0.903	0.765	0.596	0.954	78.36
	p-tau217 + Aβ42/40 + Age + Sex + APOE	0.938 (0.888–0.987)	0.839	0.926	0.813	0.938	73.06
c)	MCI group (N = 63)
	Aβ42/40	0.752 (0.629–0.874)	0.868	0.560	0.750	0.737	75.60
	Aβ42/40 + Age + Sex + APOE	0.871 (0.784–0.957)	0.868	0.760	0.846	0.792	67.26
	p-tau217	0.829 (0.725–0.934)	0.711	0.920	0.931	0.676	65.91
	p-tau217 + Age + Sex + APOE	0.899 (0.824–0.974)	0.895	0.800	0.872	0.833	59.35
	p-tau217/ Aβ42	0.856 (0.759–0.952)	0.737	0.920	0.933	0.697	64.05
	p-tau217/ Aβ42 + Age + Sex + APOE	0.914 (0.844–0.983)	0.895	0.800	0.872	0.833	57.54
	p-tau217 + Aβ42/40	0.871 (0.781–0.960)	0.816	0.880	0.912	0.759	61.84
	p-tau217 + Aβ42/40 + Age + Sex + APOE	0.912 (0.843–0.980)	0.921	0.760	0.854	0.864	59.83

^aData are from a sample of 175 participants from the BioFINDER cohort (excluding 2 CU participants with missing APOE genotype data)
CU Cognitively unimpaired, MCI Mild cognitive impairment, AUC Area under curve, BM biomarker, PPV positive predictive value, NPV Negative predictive value, AIC Akaike’s information criterion
Sensitivity, specificity, ppv, and npv were determined by using the Youden index

Back to article page

ISSN: 1758-9193

Contact us

General enquiries: journalsubmissions@springernature.com